7-[(2S,4R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)pyrrolidin-2-yl]-3,5-dihydropyrrolo[3,2-d]pyrimidin-4-one

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯并嘧啶类
• 英文名称: 7-[(2S,4R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)pyrrolidin-2-yl]-3,5-dihydropyrrolo[3,2-d]pyrimidin-4-one
• 化学式: C₁₁H₁₂F₂N₄O₃
• 分子量: 286.23
• InChiKey: GKXFBIQNLZEOAG-RWPKZCDWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1
• 重原子数：
  20
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  110
• 氢给体数：
  5
• 氢受体数：
  6

文献信息

• ANTIVIRAL AZASUGAR-CONTAINING NUCLEOSIDES
  申请人：BioCryst Pharmaceuticals, Inc.

  公开号：EP3251674A2

  公开（公告）日：2017-12-06

  Disclosed are compounds comprising an azasugar attached to a heterocyclic base, including pharmaceutically acceptable salts thereof, suitable for use in inhibiting viral RNA polymerase activity or viral replication, and treating viral infections. The compounds are characterized, in part, by favorable pharmacokinetics for the active pharmaceutical ingredient, particularly in conjunction with enteral administration, including, in particular, oral administration. Also disclosed are pharmaceutical compositions comprising one or more compounds mentioned above, or pharmaceutically acceptable salts thereof, as well as methods for preparing same. Also provided are methods for inhibiting viral RNA polymerase activity, viral replication, and treating viral infections.

  本发明公开了由连接到杂环基上的氮杂糖组成的化合物，包括其药学上可接受的盐，适用于抑制病毒 RNA 聚合酶活性或病毒复制，以及治疗病毒感染。这些化合物的部分特征是活性药物成分具有良好的药代动力学，特别是在肠道给药，尤其是口服给药的情况下。还公开了包含一种或多种上述化合物或其药学上可接受的盐的药物组合物，以及制备方法。还提供了抑制病毒 RNA 聚合酶活性、病毒复制和治疗病毒感染的方法。
• [EN] ANTIVIRAL AZASUGAR-CONTAINING NUCLEOSIDES<br/>[FR] NUCLÉOSIDES ANTIVIRAUX CONTENANT DE L'AZASUCRE
  申请人：BIOCRYST PHARM INC

  公开号：WO2014078778A2

  公开（公告）日：2014-05-22

  Disclosed are compounds comprising an azasugar attached to a heterocyclic base, including pharmaceutically acceptable salts thereof, suitable for use in inhibiting viral RNA polymerase activity or viral replication, and treating viral infections. The compounds are characterized, in part, by favorable pharmacokinetics for the active pharmaceutical ingredient, particularly in conjunction with enteral administration, including, in particular, oral administration. Also disclosed are pharmaceutical compositions comprising one or more compounds mentioned above, or pharmaceutically acceptable salts thereof, as well as methods for preparing same. Also provided are methods for inhibiting viral RNA polymerase activity, viral replication, and treating viral infections.